评估静脉氯胺酮治疗慢性每日头痛疗效与安全性的多中心随机对照试验方案:「KetHead」试验
慢性每日头痛(CDH)常对常规治疗无效,可能与三叉神经颈复合体中枢敏化及NMDA受体激活有关。本多中心、安慰剂对照、随机双盲试验拟纳入56例符合ICHD-3诊断的成人CDH患者,1:1随机接受高剂量静脉氯胺酮(1 mg/kg团注后以1 mg/kg/h输注6小时)或安慰剂(0.9%氯化钠溶液,容量与输注速度同试验药物),主要评估输注后28天头痛天数等指标。
要点
- 多中心、安慰剂对照、随机双盲试验,计划纳入56例ICHD-3诊断的成人CDH患者。
- 氯胺酮方案:1 mg/kg团注后以1 mg/kg/h输注6小时;安慰剂为等容量等速度的0.9%氯化钠溶液。
- 主要观察输注后28天头痛天数,并记录头痛强度、体力活动、情绪、睡眠、生活质量、镇痛药用量及不良反应。
核心结论
- 本试验旨在评估高剂量静脉氯胺酮输注较安慰剂能否有效且安全地改善CDH负担,该治疗可能成为难治性头痛患者安全、可负担且广泛可及的选择。
研究设计与样本
- 多中心、安慰剂对照、随机对照试验,采用两个平行组,对受试者和结局评估者设盲。
- 计划纳入56例符合ICHD-3诊断标准的成人CDH患者,按1:1随机分配。
主要发现
- 将在基线、输注后即刻以及输注后1至28天、29至56天、57至84天记录每月头痛天数、头痛强度、体力活动、情绪、睡眠、生活质量、镇痛药用量及不良反应。
关键数值与推荐
- 氯胺酮组:1 mg/kg团注后以1 mg/kg/h输注6小时。
- 安慰剂组:0.9%氯化钠溶液,容量与输注速度同试验药物,团注并输注6小时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic daily headaches (CDH) are common and associated with significant morbidity, poor quality of life, and substantial burden on the healthcare system. CDH tends to be refractory to conventional medical management and/or patients cannot afford expensive treatments. It is stipulated that CDH share a mechanism of central sensitization in the trigeminocervical complex, mediated by activation of the N-methyl-D-aspartate (NMDA) receptors. Ketamine, a non-competitive NMDA antagonist, has been used in the treatment of chronic pain, but its role in CDH has not been completely established. This trial aims to evaluate the effect of high-dose IV ketamine infusions (compared to placebo) on the number of headache days at 28 days post-infusion. METHODS: A multicenter, placebo-controlled, randomized controlled trial will be conducted with two parallel groups and blinding of participants and outcome assessors. The study will include 56 adults with a CDH diagnosis as per ICHD-3 criteria. Participants will be randomized (1:1) to either ketamine (1 mg. kg-1 bolus followed by infusion of 1 mg. kg-1. h-1 for 6 h) or placebo (0.9% saline in the same volume and infusion rate as the trial medication) bolus and infusion for 6 h. The impact on the number of monthly headache days, headache intensity, physical activity, mood, sleep, quality of life, analgesic consumption, and adverse effects will be recorded at baseline, immediately post-infusion, and from 1 to 28 days, 29 to 56 days, and 57 to 84 days after the infusion DISCUSSION: Despite advancements in treatment, many patients continue to suffer from CDH. This trial investigates whether high-dose IV ketamine infusions can effectively and safely improve the CDH burden as compared to a placebo infusion. This treatment could become a safe, affordable, and widely available option for patients living with refractory headache. TRIAL REGISTRATION: ClinicalTrials.gov NCT05306899. Registered on April 1, 2022.
引用
- Hoydonckx Y, Singh M, Gilron I, et al. Trial protocol for a multicenter randomized controlled trial to assess the efficacy and safety of intravenous ketamine for chronic daily headaches: the "KetHead" trial. Trials. 2023. PMID: 36855160. doi:10.1186/s13063-023-07186-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。